-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that the argatroban injection of Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical was accepted as a 4-type imitation
.
According to data from Minet.
com, the sales of argatroban injection in China's public medical institutions will exceed 600 million yuan in 2020, an increase of more than 40% in the first half of 2021
.
In 2021, Yangzijiang has 26 products approved for marketing, and as many as 11 injections
.
.
According to data from Minet.
com, the sales of argatroban injection in China's public medical institutions will exceed 600 million yuan in 2020, an increase of more than 40% in the first half of 2021
.
In 2021, Yangzijiang has 26 products approved for marketing, and as many as 11 injections
.
Argatroban is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect
.
.
Sales of terminal argatroban injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition pattern of public medical institutions in China
Argatroban injection was developed by Mitsubishi Tanabe, Japan.
According to data from Minet.
com, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal argatroban injection Liquid sales exceeded 600 million yuan, with a year-on-year increase of 42.
96% in 2021H1
.
There are 7 manufacturers of this product, including Tanabe Mitsubishi Pharmaceutical, Tianjin Pharmaceutical Research Institute Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Shandong New Era Pharmaceutical, etc.
, but no company has reviewed it yet
.
According to data from Minet.
com, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal argatroban injection Liquid sales exceeded 600 million yuan, with a year-on-year increase of 42.
96% in 2021H1
.
There are 7 manufacturers of this product, including Tanabe Mitsubishi Pharmaceutical, Tianjin Pharmaceutical Research Institute Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Shandong New Era Pharmaceutical, etc.
, but no company has reviewed it yet
.
Prior to this, 16 companies have reported production of Argatroban injection for review and approval.
Among them, more than 10 companies such as Sinopharm Group Guorui Pharmaceutical, Beijing Shuanglu Pharmaceutical, etc.
have reported production of 4 types of imitations.
After approval, it will be regarded as over-evaluation; the supplementary applications for consistency evaluation of Shandong New Era Pharmaceuticals and Hunan Sailong Pharmaceuticals are under review and approval
.
Who will end up with the first review?
Among them, more than 10 companies such as Sinopharm Group Guorui Pharmaceutical, Beijing Shuanglu Pharmaceutical, etc.
have reported production of 4 types of imitations.
After approval, it will be regarded as over-evaluation; the supplementary applications for consistency evaluation of Shandong New Era Pharmaceuticals and Hunan Sailong Pharmaceuticals are under review and approval
.
Who will end up with the first review?
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In the past 2021, the Yangtze River has been full of harvest, with 26 products approved for marketing, and as many as 11 injections, including the first chemical drug Class 1 new drug levornidazole phosphate disodium for injection
.
.
Note: The original text has been deleted
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that the argatroban injection of Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical was accepted as a 4-type imitation
.
According to data from Minet.
com, the sales of argatroban injection in China's public medical institutions will exceed 600 million yuan in 2020, an increase of more than 40% in the first half of 2021
.
In 2021, Yangzijiang has 26 products approved for marketing, and as many as 11 injections
.
.
According to data from Minet.
com, the sales of argatroban injection in China's public medical institutions will exceed 600 million yuan in 2020, an increase of more than 40% in the first half of 2021
.
In 2021, Yangzijiang has 26 products approved for marketing, and as many as 11 injections
.
Argatroban is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect
.
.
Sales of terminal argatroban injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition pattern of public medical institutions in China
Argatroban injection was developed by Mitsubishi Tanabe, Japan.
According to data from Minet.
com, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal argatroban injection Liquid sales exceeded 600 million yuan, with a year-on-year increase of 42.
96% in 2021H1
.
There are 7 manufacturers of this product, including Tanabe Mitsubishi Pharmaceutical, Tianjin Pharmaceutical Research Institute Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Shandong New Era Pharmaceutical, etc.
, but no company has reviewed it yet
.
According to data from Minet.
com, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal argatroban injection Liquid sales exceeded 600 million yuan, with a year-on-year increase of 42.
96% in 2021H1
.
There are 7 manufacturers of this product, including Tanabe Mitsubishi Pharmaceutical, Tianjin Pharmaceutical Research Institute Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Shandong New Era Pharmaceutical, etc.
, but no company has reviewed it yet
.
Prior to this, 16 companies have reported production of Argatroban injection for review and approval.
Among them, more than 10 companies such as Sinopharm Group Guorui Pharmaceutical, Beijing Shuanglu Pharmaceutical, etc.
have reported production of 4 types of imitations.
After approval, it will be regarded as over-evaluation; the supplementary applications for consistency evaluation of Shandong New Era Pharmaceuticals and Hunan Sailong Pharmaceuticals are under review and approval
.
Who will end up with the first review?
Among them, more than 10 companies such as Sinopharm Group Guorui Pharmaceutical, Beijing Shuanglu Pharmaceutical, etc.
have reported production of 4 types of imitations.
After approval, it will be regarded as over-evaluation; the supplementary applications for consistency evaluation of Shandong New Era Pharmaceuticals and Hunan Sailong Pharmaceuticals are under review and approval
.
Who will end up with the first review?
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In the past 2021, the Yangtze River has been full of harvest, with 26 products approved for marketing, and as many as 11 injections, including the first chemical drug Class 1 new drug levornidazole phosphate disodium for injection
.
.
Note: The original text has been deleted
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that the argatroban injection of Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical was accepted as a 4-type imitation
.
According to data from Minet.
com, the sales of argatroban injection in China's public medical institutions will exceed 600 million yuan in 2020, an increase of more than 40% in the first half of 2021
.
In 2021, Yangzijiang has 26 products approved for marketing, and as many as 11 injections
.
.
According to data from Minet.
com, the sales of argatroban injection in China's public medical institutions will exceed 600 million yuan in 2020, an increase of more than 40% in the first half of 2021
.
In 2021, Yangzijiang has 26 products approved for marketing, and as many as 11 injections
.
Argatroban is a synthetic arginine derivative that can inhibit the activity of thrombin, thereby producing an anticoagulant effect
.
.
Sales of terminal argatroban injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition pattern of public medical institutions in China
Argatroban injection was developed by Mitsubishi Tanabe, Japan.
According to data from Minet.
com, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal argatroban injection Liquid sales exceeded 600 million yuan, with a year-on-year increase of 42.
96% in 2021H1
.
There are 7 manufacturers of this product, including Tanabe Mitsubishi Pharmaceutical, Tianjin Pharmaceutical Research Institute Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Shandong New Era Pharmaceutical, etc.
, but no company has reviewed it yet
.
Hospital Hospital Hospital Enterprise Enterprise EnterpriseAccording to data from Minet.
com, in 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal argatroban injection Liquid sales exceeded 600 million yuan, with a year-on-year increase of 42.
96% in 2021H1
.
There are 7 manufacturers of this product, including Tanabe Mitsubishi Pharmaceutical, Tianjin Pharmaceutical Research Institute Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Shandong New Era Pharmaceutical, etc.
, but no company has reviewed it yet
.
Prior to this, 16 companies have reported production of Argatroban injection for review and approval.
Among them, more than 10 companies such as Sinopharm Group Guorui Pharmaceutical, Beijing Shuanglu Pharmaceutical, etc.
have reported production of 4 types of imitations.
After approval, it will be regarded as over-evaluation; the supplementary applications for consistency evaluation of Shandong New Era Pharmaceuticals and Hunan Sailong Pharmaceuticals are under review and approval
.
Who will end up with the first review?
Among them, more than 10 companies such as Sinopharm Group Guorui Pharmaceutical, Beijing Shuanglu Pharmaceutical, etc.
have reported production of 4 types of imitations.
After approval, it will be regarded as over-evaluation; the supplementary applications for consistency evaluation of Shandong New Era Pharmaceuticals and Hunan Sailong Pharmaceuticals are under review and approval
.
Who will end up with the first review?
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In the past 2021, the Yangtze River has been full of harvest, with 26 products approved for marketing, and as many as 11 injections, including the first chemical drug Class 1 new drug levornidazole phosphate disodium for injection
.
.
Note: The original text has been deleted
Source: CDE official website, Minet database
